Norwegian Action Plan for Clinical Studies — The opportunities that lie in Translational Bioinformatics and Digital Health

Amelie
Vitae Evidence
Published in
2 min readJun 20, 2021

The political paper “Action Plan for Clinical Studies (2021–2025)” was recently released in Norway by the Ministry of Health and Care Services, presenting 9 areas of focus to increase the number of studies available to Norwegian patients.

Clinical studies are essential because they give patients access to new treatment methods, contribute to better and safer patient care and sustainable healthcare services.

The government’s vision is that clinical research should be an integrated part of all clinical practice and patient care.

Those are problems areas that remain to be solved (click the links to read my post on each area):

How to make it happen?

PubGene AS develops Coremine Vitae, a new Digital Health solution for Personalised Medicine. It leverages translational bioinformatics algorithms and expert methods to make evidence-based, actionable treatments and ongoing research insights available to the patient, their local healthcare team, and the local and regional eHealth ecosystems. It is based on a CE-marked Medical Device MDD Class I, intended to aid in personalised, shared decision-making.

Today, I am kicking off a cycle of posts where I will present some of the opportunities that lie in Translational Bioinformatics and Digital Health and how Coremine Vitae will contribute to the Norwegian government’s vision by addressing the problem areas listed above.

Make sure to follow to get notifications about the following articles. I will also keep this article up to date with the list of posted articles in the series (see the links on each focus area above).

REFERENCES

Clinical Studies Action Plan:

Translational Bioinformatics

Digital Health

Coremine Vitae

--

--

Amelie
Vitae Evidence

Digital health to facilitate integrated care and well-being | Digital Therapeutics, Precision Medicine, IoT, mHealth, UX